• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
LGND

LGND

Ligand Pharmaceuticals Incorporated

NASDAQHealthcareBiotechnologyUS

USD234.40

+1.64 (+0.70%)

Rating:B+

Company Profile

CEO

Todd C. Davis

IPO Date

1992-11-18

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$232.57

Prev. Close

$232.76

Day Low

$229.52

Day High

$234.88

52W Low

$102.50

52W High

$247.38

Market Cap

$4.70B

Volume

0.15M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

40.0%

Avg Negative

14.0%

Avg Neutral

46.1%

News Feed

Ligand (LGND) Q2 Earnings & Sales Beat, 2021 Guidance Cut

Zacks Investment Research·7/30/2021·↑ positive

Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·7/29/2021·↓ negative

Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Top Estimates

Zacks Investment Research·7/29/2021·↑ positive

Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower the OmniAb® and xPloration™ antibody discovery platforms

PRNewsWire·7/28/2021·↑ positive

Ligand: 2021 Is Pivotal

Seeking Alpha·7/16/2021·↑ positive

Ligand to Report Second Quarter Financial Results on July 29, 2021

Business Wire·7/16/2021·↓ negative

Ligand (LGND) Moves 3.1% Higher: Will This Strength Last?

Zacks Investment Research·6/28/2021·↑ positive

GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement

PRNewsWire·6/2/2021·↑ positive

Ligand (LGND) Q1 Earnings Top, Bad Weather Hits Captisol Sales

Zacks Investment Research·5/4/2021·↓ negative

Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/3/2021·↓ negative